Authors

Latest:

Dr Brunner on the Role of the Dermatologist in BPDCN Diagnosis and Treatment

Patrick M. Brunner, MD, discusses how collaboration between dermatologists and oncologists is critical for both accurate diagnosis and the selection of effective treatment approaches for patients with blastic plasmacytoid dendritic cell neoplasm.

Michael W. McDermott, MD

Latest:

Test for Summarization

Kathleen N. Moore, MD, MS, discusses the challenges with utilizing immune-targeted therapy for ovarian cancer, expands on the impact of the tumor microenvironment on the effectiveness of immune checkpoint inhibitors, and details ongoing research with different treatment approaches in ovarian cancer.

Barbara Jane O’Brien, MD

Latest:

Dr O’Brien on Tucatinib Plus Trastuzumab/Capecitabine for Leptomeningeal Metastases in HER2+ Breast Cancer

Barbara Jane O’Brien, MD, discusses tucatinib plus trastuzumab and capecitabine for leptomeningeal metastases in HER2-positive breast cancer.

Bradley Monk, MD

Latest:

Future Directions in the Treatment of Recurrent or Metastatic Cervical Cancer

The panel closes their discussion by highlighting challenges in the treatment of cervical cancer, emphasizing the need for more focus on clinical trials and therapies, as well as addressing disparities in cancer care, particularly for patients of color.

David Kosoff, MD

Latest:

Immunotherapeutics Aim for Larger Role in Prostate Cancer

Highly effective tools, such as immunotherapeutic agents, have emerged for the treatment of patients with a wide range of malignancies.

Carlo Visco, MD

Latest:

Dr. Visco on Results from the MANTLE-FIRST Study in Relapsed/Refractory MCL

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Douglas W. Blayney, MD, Stanford University

Latest:

Rapid Readouts: Final Results From the Phase 3 PROTECTIVE-2 Trial

Douglas W. Blayney, MD, presents data from the 2021 American Society of Clinical Oncology Annual Meeting on the final results from the phase 3 PROTECTIVE-2 trial of Plinabulin and Pegfilgrastim in breast cancer patients treated with high febrile neutropenia risk chemotherapy.

Yucai Wang, MD, PhD, Mayo Clinic

Latest:

Diffuse Large B-Cell Lymphoma: Unmet Needs and Future Directions in Care

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Lena Winestone, MD

Latest:

Dr. Winestone on Disparities with Diagnosis in Pediatric Leukemia

Lena Winestone, MD, discusses disparities with diagnosis in pediatric leukemia.

Matthew Pierre Deek, MD

Latest:

Dr Deek on Vismodegib Plus Radiation in Locally Advanced Unresectable Basal Cell Carcinoma

Matthew P. Deek, MD, discusses multidisciplinary approaches in treating locally advanced basal cell carcinoma.

Richard Lazzaro, MD, FACS

Latest:

Dr Lazzaro on Lung Cancer Screening in High-Risk Individuals

Richard Lazzaro, MD, FACS, discusses the advantages of standard low-dose computed tomography scans in lung cancer screening in high-risk individuals, as well as future opportunities to integrate biomarker-based assays into screening protocols to improve early detection.

Andrew Kuykendall, MD

Latest:

Evolving Treatment Strategies in Polycythemia Vera: Insights Ffrom Trials and Real-World Evidence

Panelists discuss how their treatment approach has evolved based on the efficacy and safety profiles from recent trials, how updated data align with or challenge NCCN Guidelines, and the clinical implications of real-world evidence. Dr Harrison explores treatment patterns, blood count control, and the decision to switch from hydroxyurea (HU) to ruxolitinib (RUX) therapy in polycythemia vera (PV).

Tim Ho, PharmD, BCOP

Latest:

Building the Optimal Patient Experience Takes Planning and Effort

Ensuring a positive patient experience should be a top priority throughout the entire treatment journey, as higher patient satisfaction can drive improved health outcomes, treatment adherence, and quality of life.

Georgia Cancer Center at Augusta University

Latest:

Cancer Researchers and Student Athletes Are “Here to Win” for Innovation, Discovery, and Hope

Building an innovative cancer research project takes time, creativity, and most importantly, a team of scientists working together on why a new way to treat cancer or keep the cancer from spreading to other parts of the body.

Nusayba Bagegni, MD

Latest:

Dr Bagegni on the Prevalence of ILD With Trastuzumab Deruxtecan in HER2+ Breast Cancer

Nusayba Bagegni, MD, discusses the prevalence of interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Dasom (Caroline) Lee, MD

Latest:

Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL

Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.

Jeffrey A. Meyerhardt, MD, MPH, FASCO

Latest:

Dr. Meyerhardt on the Rationale for the CALGB/SWOG 80702 Trial in Colon Cancer

Jeffrey A. Meyerhardt, MD, MPH, FASCO, discusses the rationale for the randomized phase 3 CALGB/SWOG 80702 trial in colon cancer.

Terrence Friedlander, MD

Joleen M. Hubbard, MD

Latest:

SUNLIGHT QOL Data Show Positive Outcomes With Trifluridine-Tipiracil Plus Bevacizumab in CRC : With Joleen Hubbard, MD

Dr Hubbard discusses efficacy, safety, and quality of life outcomes from the SUNLIGHT trial of trifluridine-tipiracil plus bevacizumab in metastatic CRC.

Leah Backhus, MD, MPH, FACS

Latest:

Dr Backhus on Defining Borderline-Resectable Lung Cancer

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of borderline resectable lung cancer.